This is an audio version of the Wikipedia Article:
[ Ссылка ]


00:01:10 1 History
00:03:38 1.1 Acquisitions
00:03:47 1.1.1 Aptein Inc.
00:06:54 1.1.2 Drug Royalty Corporation Inc.
00:08:20 1.1.3 Oxford Glycosciences
00:10:06 1.1.4 Genencor
00:12:02 1.2 Collaborations
00:17:03 2 Products and pipeline
00:22:06 3 Patents
00:24:09 3.1 List of Patents
00:24:18 3.2 Patent Dispute with MorphoSys
00:25:07 4 Publications
00:28:39 5 Management and notable people
00:32:03 6 Awards
00:32:32 7 See also



Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone.

Listen on Google Assistant through Extra Audio:
[ Ссылка ]
Other Wikipedia audio articles at:
[ Ссылка ]
Upload your own Wikipedia articles through:
[ Ссылка ]
Speaking Rate: 0.922681035303135
Voice name: en-AU-Wavenet-B


"I cannot teach anybody anything, I can only make them think."
- Socrates


SUMMARY
=======
Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using phage display and ribosome display technology.
Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug. Humira, the brand name of adalimumab, is an anti-TNF antibody discovered by CAT as D2E7, then developed in the clinic and marketed by Abbott Laboratories. The company was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved drug for systemic lupus in more than 50 years.Founded in 1989, CAT was acquired by AstraZeneca for £702m in 2006. AstraZeneca subsequently acquired MedImmune LLC, which it combined with CAT to form a global biologics division called MedImmune. CAT was often described as the 'jewel in the crown' of the British biotechnology industry and during the latter years of its existence was the subject of frequent acquisition speculation.

свернуть